Royalty Pharma plc (NASDAQ:RPRX) Stock Position Trimmed by Tidal Investments LLC

Tidal Investments LLC decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 19.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,375 shares of the biopharmaceutical company's stock after selling 9,371 shares during the period. Tidal Investments LLC's holdings in Royalty Pharma were worth $979,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RPRX. Adage Capital Partners GP L.L.C. lifted its stake in shares of Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock worth $432,862,000 after acquiring an additional 5,069,127 shares in the last quarter. Swedbank AB increased its holdings in Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after purchasing an additional 1,136,800 shares during the last quarter. Geode Capital Management LLC increased its holdings in Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock worth $186,846,000 after purchasing an additional 46,765 shares during the last quarter. Norges Bank acquired a new position in shares of Royalty Pharma in the 4th quarter valued at approximately $124,498,000. Finally, Northern Trust Corp boosted its stake in shares of Royalty Pharma by 12.8% during the 4th quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock valued at $84,959,000 after buying an additional 376,619 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock traded up $0.29 during trading hours on Friday, reaching $32.93. The company's stock had a trading volume of 534,525 shares, compared to its average volume of 3,458,566. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.32. The company's 50 day simple moving average is $32.32 and its 200 day simple moving average is $30.34. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market cap of $18.52 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The firm had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.67%. Royalty Pharma's dividend payout ratio is currently 47.57%.

Wall Street Analyst Weigh In

RPRX has been the subject of a number of research analyst reports. Morgan Stanley assumed coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They issued an "overweight" rating and a $51.00 price target for the company. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Finally, Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a report on Tuesday, May 20th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.